Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Bellicum Pharmaceuticals, Inc. BLCM NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Bellicum Pharmaceuticals, Inc. (BLCM) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 9 Buy.

BLCM Analyst Ratings

Buy
9
Ratings
9 Buy
Based on 9 analysts giving stock ratings to Bellicum Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
9 100%
100%
Buy
9 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

CLLS
CLLS
Cellectis S.A.
$4.09
-1.68%
 ADAP
ADAP
Adaptimmune Therapeutics plc
$0.05
-3.00%
 ATRA
ATRA
Atara Biotherapeutics, Inc.
$5.24
+1.75%
 AFMD
AFMD
Affimed N.V.
$0.18
+0.00%
 CALA
CALA
Calithera Biosciences, Inc.
$0.00
+200.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message